LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today the commencement of a 30 patient Phase II clinical trial for its new HIV-1 anti-viral therapy, SpirH™. SpirH™ is being studied to determine its potential to delay the onset of full-blown AIDS when used as a mono-therapy in early stage infection.
